CNS Pharmaceuticals, Inc. (CNSP) company profile
Close on Nov 17, 2026Market cap $6.07MP/E –Yield –
About CNS Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious neurological conditions and cancers. The company seeks to build a portfolio of differentiated preclinical and clinical-stage drug candidates by identifying, acquiring, or in-licensing assets that offer defined biological rationales and clear regulatory pathways. Historically centered on advancing treatments for glioblastoma multiforme, including investigational compounds such as TPI 287 and Berubicin designed to cross the blood-brain barrier, the company has pivoted toward broader opportunities across neurology and oncology. Its primary target populations comprise patients diagnosed with severe neurodegenerative disorders and various oncological malignancies.
The company operates principally within the United States, maintaining its corporate headquarters in Houston, Texas. Its strategic activities encompass evaluating global asset acquisition and in-licensing opportunities across the worldwide biopharmaceutical sector. Development operations are led by an executive management team overseeing clinical, regulatory, and corporate initiatives.
Summary of the business section of CNS Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CNS Pharmaceuticals, Inc.
- Headquarters
- Houston, TX
- Address
- 2100 West Loop South, Suite 900 77027
- Phone
- 1-800-946-9185
- Website
- cnspharma.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- CNSP
- Exchange
- Nasdaq
- IPO date
- Nov 8, 2019
- Shares outstanding
- 1M, Aug 11, 2026
- Public float
- $8.78M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Jul 22, 2025; 1-for-50 reverse, Feb 21, 2025; 1-for-50 reverse, Jun 5, 2024; 1-for-30 reverse, Mar 31, 2023; 1-for-30 reverse, Nov 29, 2022
- SEC CIK
- 1729427
- CUSIP
- 18978H508
- ISIN
- US18978H5081
- FIGI
- BBG00PM24T16
- Share class FIGI
- BBG00PM24TS7
- LEI
- 529900FDJ7WGF2Q7UN44
- EIN
- 82-2318545
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John M. Climaco | Chief Executive Officer, Director | 215,676 |
| Rami Levin | CEO and President | 4,750 |
| Eric Faulkner | Chief Technology Officer | – |
| Steve O'Loughlin | Chief Financial Officer | – |
| Christopher Downs | Chief Financial Officer | 103,438 |
| Michal Fisher | Director | 2,000 |
| Faith L. Charles | Director | 7,100 |
| Jeffry R. Keyes | Director | 11,100 |
| Bettina M. Cockroft | Director | – |
| Amy Mahery | Director | – |
| Jerzy Gumulka | Director | 43,006 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.17M | $964.58K | $724.81K | $0 | – |
| FY2024 | $1.10M | $677.72K | $982.69K | $0 | – |
| FY2023 | $624.35K | $846.87K | $671.67K | $53 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| John Climaco Former Chief Executive Officer | $580.00K | $269.59K | $319.00K | $1.17M | +6% |
| Christopher Downs Senior Vice President – Finance, (Former Chief Financial Officer) | $450.00K | $134.81K | $144.00K | $728.81K | +17% |
| Sandra Silberman Former Chief Medical Officer | $495.00K | $67.42K | $158.40K | $720.82K | +99% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 8, 2019
- Offer price
- $4.00
- Securities offered
- 2,125,000
- Gross proceeds
- $8.50M
- Exchange
- Nasdaq
- First trading day
- Nov 8, 2019
- First-day close
- $4.57+14.3%
- Lock-up ends (est.)
- May 6, 2020
“Per Share Total Initial public offering price $ 4.00 $ 8,500,00 Underwriting discounts and commissions(1)(2) $ 0.28 $ 595,000 Proceeds to us, before expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had eight full time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 18, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 12, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 24, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 27, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 21, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 18, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 18, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 8, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 5, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?